PACB
NASDAQ · Life Sciences Tools & Services
Pacific Biosciences Of Calif
$2.27
-0.28 (-10.98%)
Financial Highlights (FY 2026)
Revenue
196.25M
Net Income
-670,170,146
Gross Margin
31.2%
Profit Margin
-341.5%
Rev Growth
+7.6%
D/E Ratio
120.65
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 31.2% | 31.2% | 33.8% | 33.8% |
| Operating Margin | -346.1% | -311.5% | 20.7% | 19.4% |
| Profit Margin | -341.5% | -324.4% | 16.0% | 14.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 196.25M | 182.32M | 209.60M | 233.24M |
| Gross Profit | 61.27M | 56.92M | 70.95M | 78.95M |
| Operating Income | -679,318,198 | -567,991,804 | 43.31M | 45.34M |
| Net Income | -670,170,146 | -560,342,931 | 33.56M | 32.81M |
| Gross Margin | 31.2% | 31.2% | 33.8% | 33.8% |
| Operating Margin | -346.1% | -311.5% | 20.7% | 19.4% |
| Profit Margin | -341.5% | -324.4% | 16.0% | 14.1% |
| Rev Growth | +7.6% | +7.6% | +11.0% | +6.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 447.00M | 447.00M | 210.64M | 202.72M |
| Total Equity | 3.70M | 3.70M | 247.53M | 237.21M |
| D/E Ratio | 120.65 | 120.65 | 0.85 | 0.85 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -672,929,561 | -593,908,475 | 52.44M | 66.49M |
| Free Cash Flow | — | — | 18.17M | 20.81M |